CA 19-9 assay
A blood test used to measure the level of CA 19-9 antigen in the blood
CA 19-9 assay | |
---|---|
[[File:|250px|alt=|]] | |
Pronunciation | |
Synonyms | |
Reference Range | |
Calculator | |
Purpose | Measures CA 19-9 antigen levels |
Test of | Pancreatic cancer, cholangiocarcinoma, and other conditions |
Based on | |
ICD-10-PCS | |
ICD-9-CM | |
MeSH | |
OPS-301 Code | |
Other Codes | |
MedlinePlus | |
eMedicine | |
LOINC | |
HCPCS-L2 | |
The CA 19-9 assay is a blood test used primarily to monitor pancreatic cancer and other types of gastrointestinal cancer. CA 19-9, or carbohydrate antigen 19-9, is a tumor marker that can be elevated in certain types of cancer and other conditions.
Background[edit | edit source]
CA 19-9 is a glycoprotein that is expressed on the surface of certain cancer cells. It was first identified in the early 1980s and has since been used as a marker for pancreatic cancer and cholangiocarcinoma.
Clinical Use[edit | edit source]
The CA 19-9 assay is not used as a screening test for cancer because it is not specific enough. However, it is useful in the following scenarios:
- Monitoring treatment response: In patients with known pancreatic cancer, CA 19-9 levels can be used to monitor the effectiveness of treatment. A decrease in CA 19-9 levels may indicate a positive response to therapy.
- Detecting recurrence: After treatment, rising CA 19-9 levels may suggest a recurrence of cancer.
- Prognostic indicator: Higher levels of CA 19-9 at diagnosis may be associated with a poorer prognosis.
Limitations[edit | edit source]
CA 19-9 is not specific to pancreatic cancer and can be elevated in other conditions, such as:
Additionally, some individuals do not produce CA 19-9 due to a lack of the Lewis antigen, which is necessary for the synthesis of CA 19-9. This limits the test's utility in these patients.
Procedure[edit | edit source]
The CA 19-9 assay involves a simple blood draw. The blood sample is then analyzed in a laboratory to measure the level of CA 19-9 antigen. Results are typically reported in units per milliliter (U/mL).
Interpretation of Results[edit | edit source]
Normal levels of CA 19-9 are generally considered to be below 37 U/mL. However, the interpretation of results should be done in the context of the patient's clinical picture and other diagnostic findings.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD